Cargando…

Near-infrared photobiomodulation of blood reversibly inhibits platelet reactivity and reduces hemolysis

Photobiomodulation (PBM) in the red/near-infrared (R/NIR) spectral range has become widely recognized due to its anti-inflammatory and cytoprotective potential. We aimed to assess the effects of blood PBM on platelets function and hemolysis in an in vitro setting. Porcine blood samples were separate...

Descripción completa

Detalles Bibliográficos
Autores principales: Walski, Tomasz, Grzeszczuk-Kuć, Karolina, Gałecka, Katarzyna, Trochanowska-Pauk, Natalia, Bohara, Raghvendra, Czerski, Albert, Szułdrzyński, Konstanty, Królikowski, Wiesław, Detyna, Jerzy, Komorowska, Małgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904845/
https://www.ncbi.nlm.nih.gov/pubmed/35260751
http://dx.doi.org/10.1038/s41598-022-08053-y
Descripción
Sumario:Photobiomodulation (PBM) in the red/near-infrared (R/NIR) spectral range has become widely recognized due to its anti-inflammatory and cytoprotective potential. We aimed to assess the effects of blood PBM on platelets function and hemolysis in an in vitro setting. Porcine blood samples were separated into four aliquots for this study, one of which served as a control, while the other three were subjected to three different NIR PBM dosages. The platelet count and functions and the plasma free haemoglobin and osmotic fragility of red blood cells were measured during the experiment. The control group had a considerable drop in platelet number, but the NIR exposed samples had more minimal and strictly dose-dependent alterations. These modifications were consistent with ADP and collagen-induced platelet aggregation. Furthermore, red blood cells that had received PBM were more resistant to osmotic stress and less prone to hemolysis, as seen by a slightly lower quantity of plasma free hemoglobin. Here we showed under well-controlled in vitro conditions that PBM reversibly inhibits platelet activation in a dose-dependent manner and reduces hemolysis.